R. K. Singh A. K. Tripathi A. Srivastava A. P. Singh Vol 9(4), 94-102 DOI- http://dx.doi.org/10.5455/ijlr.20180927060618
The therapeutic efficacy of various antitrypanosomal drugs viz. diminazine aceturate, isometamedium chloride HCl and quinopyramine sulphate alone or in combination with vitamin E (antioxidant) were evaluated in naturally infected equines with T. evansi. Evaluation was done on the basis of alterations in the hemato-biochemical, oxidative stress parameters and percent recovery assessment on day 0 pretreatments, day 7th and day 14th post treatment. It can be infer from present study that all three drugs alone or along with vitamin E were effective against the trypanosomosis in equines but the extent of improvement in terms of hemato-biochemical values, oxidative stress parameters and percent recovery was observed maximum in the treatment with diminazine aceturate with vitamin E followed by isometamidium chloride hydrochloride with vitamin E and least with the quinapyramine sulphate. Therefore, the order of comparative therapeutic efficacy of anti-trypanosomal drugs in the present study has been found as diminazene aceturate with vitamin E, maximally effective followed by isometamidium chloride HCL with vitamin E and Quinapyramine sulphate was found to be least effective. Hence, diminazine aceturate along with vitamin E (antioxidant) could be successfully used in the treatment of equine trypanosomosis.
Keywords : Equine Hemato-Biochemical Oxidative Stress Percent Recovery Therapeutic Efficacy Trypanosomosis
Majority of the equines (97.96%) in India are owned by landless, small and marginal farmers belonging to socio-economically deprived communities in rural and semi-urban areas is mostly unorganized. Surra mostly occurs as an endemic disease in northern and eastern India and treated horses have a high risk of re-infection (Laha and Sasmal, 2008). The field control of animal trypanosomiasis has, over the years, relies on two broad strategies: using chemotherapeutic agents on infected animals and vector control. In general, however, the chemotherapeutic approach is used much more widely than vector control because it is easier to kill the trypanosomes than the flies (WHO 1998). Current methods of treatment of trypanosomes are still unsatisfactory usually associated with severe side effects and indiscriminate use of anti-trypanosomal drugs results into the emergence of drug resistance (Kaminsky and Brun, 1998). Keeping in view of the above facts this study was done to compare in vivo efficacy of the three commonly used chemotherapeutic drugs alone and in combination with the vitamin E (Diminazene aceturate, Quinapyramine sulphate and isometamidium chloride HCl) on equines clinically infected with T. evansi.
Materials and Methods
The study was performed at teaching veterinary clinical complex (TVCC), Uttar Pradesh Pandit Deen Dayal Upadhyaya Pashu-Chikitsa Vigyan Vishwavidyalaya Evam Go Anusandhan Sansthan, Mathura (DUVASU) from April, 2014 to March, 2015. The comparative efficacies of three anti-trypanosomal drugs (diminazine aceturate, quinapyramine sulphate and isometamidium chloride hydrochloride) alone and along with vitamin-E as antioxidants were used in standard dosage in positive cases of Trypanosoma evansi by giemsa stained thin blood smear. Prior to administration of antitrypanosomal drugs, animals were administered supportive therapies. These animals were grouped in seven groups with six equines in each groups (n=6).
Group I | Positive cases of Trypanosoma evansi treated by diminazene aceturate (@ 7mg/kg body wt. by deep I/M rout) along with supportive therapy. |
Group II | Positive cases of Trypanosoma evansi treated by diminazene aceturate (@ 7mg/kg body wt. by deep I/M route) with Vitamin- E (@ 6 IU/kg body wt. orally for 2weeks) as antioxidant along with supportive therapy. |
Group III | Positive cases of Trypanosoma evansi treated by quinapyramine sulphate (@ 5mg/kg body wt. by S /C route) along with supportive therapy |
Group IV | Positive cases of Trypanosoma evansi treated by quinapyramine sulfate (@ 5mg/kg body wt. by S /C route) with Vitamin -E (@ 6 IU/kg body wt. orally for 2weeks) as antioxidant along with supportive therapy. |
Group V | Positive cases of Trypanosoma evansi treated by isometamidium Chloride HCl (@ 0.5 mg/kg body wt. by deep I/M route) along with supportive therapy. |
Group VI | Positive cases of Trypanosoma evansi treated by isometamidium Chloride HCl (@ 0.5 mg/kg body wt. by deep I/M route) with Vitamin-E (@ 6 IU/kg body wt. orally for 2weeks) as antioxidant along with supportive therapy. |
Group VII | Apparently healthy equine were kept as control |
Supportive therapy was done as per need of the animal like fluid therapy, antipyretics, haematinics, antibiotics, antihistaminics etc. The therapeutic efficacy of above anti-trypanosomal drugs were evaluated on the basis of alterations in the hemato-biochemical, oxidative stress parameters and percent recovery assessment on day 0 pre-treatment, day 7th and 14th post treatment. All the positive cases of each group were thoroughly examined by clinical examination and blood smear examination on the day 0 (pretreatment), 7th and 14th after treatment. Percent recovery assessment was done on the basis of improvement in terms of disappearance of clinical signs and number of blood smear negative equines on the day 7th and 14th after treatment (% Recovery = n/6×100, where n= number of blood smear negative and clinically improved equines). Those animals which were found blood smear positive with clinical signs on the day 7th after treatment were again treated with the same anti-trypanosomal drug along with supportive therapy. Hemato-biochemical and oxidative stress parameter analysis were done on the day 0 (pre-treatment), 7th and 14th (post-treatment). To assess the therapeutic efficacy of different anti-trypanosomal drugs, parameters viz hemoglobin, TEC, PCV, TLC, and DLC were assessed using hematology auto analyzer (Diatron’s Abacus Hematology Analyzer, Wien, Australia).
For biochemical study serum was separated and estimation of total protein (Biuret method), albumin (BCG Dye method), globulin (Total protein-albumin), creatinine (Jaff’s method), blood urea nitrogen (NED-dye method) and ALT by Modified UV (IFCC) with the help of BS-120 Chemistry Analyzer (Shenzhen Mindray Biochemical Electronics Co. Ltd.) using Span diagnostic kits (Span Diagnostics Ltd, Sachin, Surat, India). Estimation of glucose was done on the spot of sample collection by using glucometer (Gluco Chek, Aspen Diagnostics (P) LTD. Delhi-33, India). To evaluate the oxidative stress parameters the extent of lipid peroxidation was evaluated in terms of MDA (malondialdehyde) production, determined by thiobarbituric acid (TBA) method. Superoxide dismutase (SOD) and catalase activity was estimated in the RBC hemolysate as per standard procedure. The data generated from the present study was subjected to the test of significance (t-test) as per the method described (Thrusfield, 2008).
Results and Discussion
Therapeutic Efficacy on the Basis of Hemato-Biochemical Alterations
There was a significant reduction (p<0.05) in hemoglobin concentration, packed cell volume and total erythrocyte count (at day, 0) in all the treatment groups of equines in comparison with the healthy control (Table 1). There was a significant increase (p<0.05) in the hemoglobin concentration , packed cell volume and total erythrocyte count at the day 7th and day 14th after the treatment in all treatment groups with highest recovery in group II followed by group VI and minimum in group III. Therefore in terms of improvement in treated groups of equines best recovery was assessed in treatment with diminazene aceturate with vitamin E, followed by isometamidium chloride hydrochloride with vitamin-E and least with quinopyramine sulphate. The present findings of decrease in Hb, PCV and TEC in cases of trypanosomiasis are in agreement with the findings of Kumar et al. (2011). The total leukocyte count, neutrophils and lymphocytes were significantly higher (p<0.05) (at day, 0) in all the treatment groups of equines in comparison with the healthy control.
Table 1: Hematological alterations in various groups of equines suffering from Trypanosoma evansi infection (Mean ± SE)
Groups | Hb (gm/dl) | TEC (×106/µl) | PCV (%) | ||||||
Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | |
I | 6.78 ±0.14Aa | 10.80 ±0.06Db | 12.50 ±0.15Cc | 4.02 ±0.02Aa | 6.89 ±0.02Cb | 7.04 ±0.02BCc | 20.00 ±0.51Aca | 32.78 ±0.14Db | 34.5±0.48ABc |
II | 6.85±0.08Aa | 11.95 ±0.21Eb | 13.47 ±0.09Dc | 4.16±0.08Aa | 7.35 ±0.12Db | 7.85 ±0.10Dc | 20.45 ±0.30Aa | 35.65±0.70Eb | 39.56±0.23Ec |
III | 6.78 ±0.09Aa | 7.55 ±0.11Ab | 11.53 ±0.084Ac | 4.24±0.10Aa | 5.47 ±0.13Ab | 6.65 ±0.15Ac | 20.63 ±0.32Aa | 22.33±0.20Ab | 34.27±0.18Ac |
IV | 6.78 ±0.06Aa | 7.95 ±0.11Bb | 11.87 ±0.05Bc | 4.15±0.08Aa | 5.70 ±0.12Ab | 6.90 ±0.12ABc | 20.40 ±0.24Aa | 23.72±0.42Bb | 35.5±0.16BCc |
V | 6.90 ±0.12Aa | 8.03 ±0.10Bb | 12±0.11Bc | 4.22±0.10Aa | 5.78 ±0.10Ab | 7.17 ±0.10BCc | 20.80 ±0.48Aa | 24.13±0.28Bb | 36.53±0.62CDc |
VI | 6.88 ±0.19Aa | 9.13 ±0.13Cb | 12.47±0.147Cc | 4.07±0.06Aa | 6.3 ±0.12Bb | 7.28 ±0.10Cc | 20.17 ±0.30Aa | 27.38±0.43Cb | 37.38±0.41Dc |
VII | 13.80 ±0.06B | 14.00 ±0.07F | 14.05±0.08E | 8.83±0.05B | 8.87±0.08E | 9.00 ±0.07E | 40.13 ±0.41B | 40.93±0.39F | 41.38±0.32F |
Groups | TLC(×103/µl) | Neutrophils (%) | Lymphocytes (%) | ||||||
Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | |
I | 16.45±0.13Bb | 13.02±0.06Ba | 12.75±0.08Ba | 80.5±0.76Bb | 69±0.36Ba | 67.5±0.56Da | 15.67±0.49Aa | 26±1.13Bb | 28.67±1.14Ab |
II | 15.80±0.62Bb | 12.95±0.06Bav | 12.67±0.07Ba | 80.5±0.50Bc | 69±0.52Bb | 67.33±0.49CDa | 15.33±0.33Aa | 26.5±0.85Bb | 28.33±0.92Ab |
III | 16.38±0.16Bc | 15.45±0.15Cb | 13.77±0.14Ca | 79.67±0.84Bc | 75.5±0.85Cb | 68.17±0.54Da | 15±0.63Aa | 19.17±0.87Ab | 26.17±1.01Ac |
IV | 16.27±0.14Bc | 15.25±0.16Cb | 13.67±0.05Ca | 79.33±0.84Bc | 75.17±1.01Cb | 67.83±0.75Da | 15.33±0.42Aa | 19.83±1.11Ab | 26.67±0.76Ac |
V | 16.40±0.12Bc | 15.3±0.12Cb | 13.63±0.12Ca | 80.83±0.70Bc | 74.17±0.60Cb | 65.17±0.31Ba | 15±0.52Aa | 20±0.45Ab | 28.67±0.65Ac |
VI | 16.33±0.13Bc | 15.28±0.10Cb | 13.6±0.13Ca | 81.33±0.72Bc | 73.5±0.76Cb | 65.83±0.48BCa | 14±0.45Aa | 20.67±0.88Ab | 28±0.82Ac |
VII | 11.08±0.06A | 11.25±0.08A | 11.21±0.07A | 56.17±0.48A | 54.5±0.50A | 54.67±0.42A | 38.83±0.79B | 40.5±0.22C | 40±0.36B |
Mean with different superscript (A, B, C, D) in columns are differing significantly in between the groups, otherwise non-significant; Mean with different superscript (a, b, c) in rows are differing significantly in between the intervals, otherwise non-significant.
There was a significant decrease (p<0.05) in the total leukocyte count, percent neutrophils and significant increase (p<0.05) in the lymphocytes at the day 7th and day 14th after the treatment in all treatment groups with highest recovery in group II followed by group VI and minimum in group III. The increased WBC and neutrophil counts are indicative of increased host defence against the infection; contribute to the development of phagocytes and antibodies against the recognizable antigens of parasite origin (Kumar et al., 2012). The observed decrease in the lymphocyte count could be a result of the corresponding increase of neutrophil count during the infection. Leukocytosis and lymphocytopenia found in our study are in agreement with the findings of Abeer et al. (2011). Therefore, in term of improvement in total leukocyte count, neutrophils and lymphocyte percentage in treated groups of equines, best recovery was assessed in treatment with diminazene aceturate with vitamin E group, followed by Isometamidium chloride hydrochloride with vitamin E group and quinopyramine sulphate group.
Significant reduction (p<0.05) in the serum albumin concentration (at day, 0) was observed in all the treatment groups of equines in comparison with the healthy control (Table 2). However, there was a significant increase (p<0.05) in the albumin concentration at day 7th and day 14th after the treatment in all treatment groups with highest recovery in group II followed by group I & VI and minimum in group III. There was a significant increase (p<0.05) in globulin concentration (at day, 0) in all the treatment groups of equines in comparison with the healthy control. However, there was a significant decrease (p<0.05) in the globulin concentration at day 7th and day 14th after the treatment in all treatment groups with highest recovery in group II followed and minimum in group III. These findings of present investigations are in accordance with findings of Hilali et al. (2006). Values of serum albumin and serum globulin were found to be significantly elevated after treatment with different drugs on day 7th and day 14th post-treatment in all the groups but best recovery was assessed in Group II followed by group VI and minimum in group III.
There was a significant reduction (p<0.05) in blood glucose concentration (at day, 0) in all the treatment groups of equines in comparison with the healthy control (Table 2). However, there was a significant increase (p<0.05) in the blood glucose concentration at day 7th and day 14th after the treatment in all treatment groups with highest recovery in group I & II followed by group V & VI and minimum in group III. Our findings of hypoglycemia might have occurred due to the increase of the metabolic rate caused by fever has been reported in infected animals, hepatocyte degeneration or glucose consumption by the trypanosomes for their metabolism (Silva et al., 1997). Therefore, in terms of improvement in blood glucose concentrations in treated groups of equines best recovery was assessed in Group I & II followed by group V & VI and minimum in group III. There was a significant increase (p< 0.05) in serum blood urea nitrogen and serum creatinine concentration (at day, 0) in all the treatment groups of equines in comparison with the healthy control.
Table 2: Biochemical alterations in various groups of equines suffering from Trypanosoma evansi infection (Mean ± SE)
Groups | Total Protein (gm/dl) | Albumin (gm/dl) | Globulin (gm/dl) | ||||||
Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | |
I | 7.27±0.02 | 7.32±0.03 | 7.37±0.02 | 1.80±0.07Ba | 3±0.04Cb | 3.22±0.05Cc | 5.46±0.07Bb | 4.32±0.06Ba | 4.15±0.05Aa |
II | 7.32±0.03 | 7.38±0.05 | 7.48±0.03 | 1.78±0.09Ba | 3.02±0.08Cb | 3.27±0.06Cc | 5.53±0.11Bb | 4.37±0.09Ba | 4.21±0.07Aa |
III | 7.38±0.03 | 7.55±0.04 | 7.62±0.03 | 1.59±0.02Aa | 2.26±0.06Ab | 2.87±0.02Ac | 5.79±0.03 Cc | 5.29±0.08Eb | 4.75±0.04Ca |
IV | 7.4±0.04 | 7.45±0.03 | 7.5±0.03 | 1.56±0.04Aa | 2.25±0.06Ab | 2.89±0.02Ac | 5.84±0.06 Cc | 5.2±0.08DEb | 4.59±0.05BCa |
V | 7.4±0.04 | 7.5±0.04 | 7.57±0.04 | 1.66±0.02ABa | 2.56±0.01Bb | 3.03±0.02Bc | 5.74±0.04 Cc | 4.95±0.03Cb | 4.54±0.04Ba |
VI | 7.38±0.03 | 7.53±0.02 | 7.62±0.04 | 1.61±0.05Aa | 2.53±0.04Bb | 3.01±0.05Bc | 5.78±0.08Cc | 5.01±0.04CDb | 4.6±0.07BCa |
VII | 7.25±0.06 | 7.32±0.05 | 7.35±0.06 | 3.15±0.05C | 3.18±0.06D | 3.3±0.04C | 4.17±0.08A | 4.07±0.09A | 4.05±0.08A |
Groups | Blood Glucose (mg/dl) | BUN (mg/dl) | Creatinine (mg/dl) | ||||||
Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | |
I | 53.33 ±1.02Aa | 77.67±0.99Cb | 83.17±1.62Bc | 58.39±0.37Bb | 23.22±0.36Ba | 22.37±0.26Ba | 2.27±0.05Cc | 1.43±0.03Cb | 1.12±0.04Aa |
II | 53.17±0.87 Aa | 77.17±1.01 Cb | 82.67±1.52Bc | 58.41±0.58Bb | 22.95±0.28Ba | 22.2±0.29Ba | 2.06±0.08Bc | 1.28±0.03Bb | 1.02±0.05Aa |
III | 53.67±0.84 Aa | 64.17±0.70Ab | 74.17±0.48Ac | 58.01±0.67Bc | 32.88±0.28Eb | 24.04±0.05Da | 2.63±0.05Dc | 2.25±0.04Db | 1.97±0.01Ca |
IV | 53.83±0.95 Aa | 63.5±0.72Ab | 74±0.58Ac | 57.87±0.57Bc | 32.6±0.29DEb | 23.97±0.06Da | 2.57±0.07Dc | 2.23±0.05Db | 1.96±0.01Ca |
V | 53.17±0.87 Aa | 67.67±0.42Bb | 76.83±0.48Ac | 58.2±0.44Bc | 31.7±0.23CDb | 23.19±0.23Ca | 2.66±0.04Dc | 2.35±0.07Db | 1.71±0.12Ba |
VI | 53±0.86 Aa | 67.33±0.42Bb | 76.5±0.56Ac | 57.88±0.39Bc | 31.57±0.20Cb | 23.13±0.21Ca | 2.66±0.05Db | 2.39±0.08Db | 1.58±0.14Ba |
VII | 88±0.63B | 88.83±0.87D | 89±0.52C | 18.83±0.40A | 18.17±0.48A | 19.17±0.17A | 1.08±0.03A | 1.02±0.05A | 1±0.04A |
Groups | ALT (IU/L) | AST (IU/L) | ALP (IU/L) | ||||||
Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | |
I | 60.17±0.48Bc | 22.5±0.22Bb | 21±0.36Ba | 218.5±0.43 | 218.78±0.57 | 218.43 ±0.53 | 185.67±0.49 | 186.33±0.67 | 185.83±0.60 |
II | 60±0.63Bb | 22±0.36Ba | 20.83±0.31Ba | 217.67±0.33 | 217.98±0.30 | 217.77 ±0.60 | 185.67±0.48 | 185.67±0.67 | 185±0.45 |
III | 58.5±0.76Bc | 32±0.58Db | 23.5±0.22Da | 219±0.45 | 218.17±0.54 | 217.33 ±0.72 | 186.17±0.60 | 185.83±0.48 | 185.17±0.31 |
IV | 58.17±0.60Bc | 31.17±0.60Db | 23.17±0.31CDa | 217.83±0.70 | 218.33±0.49 | 218.17 ±0.91 | 186±0.58 | 185.67±0.56 | 185.67±0.33 |
V | 59±0.58Bc | 27.5±0.43Cb | 22.33±0.33Ca | 218.17±0.60 | 217.83±0.70 | 217±0.58 | 185.5±0.62 | 185.67±0.56 | 186±0.36 |
VI | 58.67±0.80Bc | 27.5±0.43Cb | 22.83±0.40CDa | 217.5±0.67 | 217.33±0.76 | 217.33 ±0.49 | 185±0.68 | 185.17±0.40 | 185.67±0.88 |
VII | 20.17±0.70A | 19.33±0.49A | 19.5±0.22A | 219±0.36 | 218.5±0.62 | 218.50 ±0.50 | 180.17±0.70 | 179.5±0.56 | 179.83±0.48 |
Mean with different superscript (A, B, C, D) in columns are differing significantly in between the groups, otherwise non-significant; Mean with different superscript (a, b, c) in rows are differing significantly in between the intervals, otherwise non-significa
However, there was a significant decrease (p< 0.05) in serum blood urea nitrogen and serum creatinine after the treatment in all treatment groups with highest recovery in group II followed by group I & VI and minimum in group III. These elevations suggest renal injury and associated glomerular dysfunction (Anosa, 1988a). Therefore, in term of improvement in blood urea nitrogen and serum creatinine concentration in treated groups of equines best recovery was assessed in Group II followed by group I & VI and minimum in group III. There was a significant increase (p<0.05) in serum ALT concentration (at day, 0) in all the treatment groups of equines in comparison with the healthy control (Table 2). However, there was a significant decrease (p<0.05) in the serum ALT concentration at day 7th and day 14th after the treatment in all treatment groups with highest recovery in group II followed by group I & VI and minimum in group III. The causes of the elevation of ALT levels may be due to necrosis of the liver, skeletal muscles and kidneys (Abeer et al., 2011). Therefore, in term of improvement in serum ALT concentration in treated groups of equines best recovery was assessed in Group II followed by group I & VI and minimum in group III.
Therapeutic Efficacy on the Basis of Oxidative Stress Parameters
There was a significant increase (p<0.05) in level of LPO concentration and decrease in SOD and catalase concentration in erythrocyte hemolysate (at day, 0) in all the treatment groups of equines in comparison with the healthy control (Table 3). However, there was a significant decrease (p<0.05) in the level of LPO concentration and increase in SOD and catalase concentration at day 7th and day 14th after the treatment in all treatment groups with highest recovery in group II followed by group VI and minimum in group III. In present study the increased level of lipid peroxidation in erythrocytes of affected horses are indication of elevated oxidative stress (Chaudhuri et al., 2008). Thus, higher production of peroxyl radicals and consequent elevated LPO concentration renders the erythrocytes more fragile and prone to lysis. Therefore, in term of improvement in LPO, SOD and catalase concentration in treated groups of equines best recovery was assessed in Group II followed by group VI and minimum in group III.
Therapeutic Efficacy on the Basis of Percent Recovery Assessment
Recovery assessment was done on the basis clinical improvement in terms of disappearance of clinical signs & parasitological examination, the percent recovery shown by the diminazine aceturate (group I) and diminazine aceturate with vitamin- E (group II) on day 7th and day 14th post-treatment was found to be 100 percent. The percent recovery shown by isometamidium chloride hydrochloride (group V) and isometamidium chloride hydrochloride with vitamin- E(group VI) on day 7th and day 14th post-treatment was found to be 83.33 percent and 100 percent respectively. The percent recovery shown by quinapyramine sulphate (group III) and quinapyramine sulphate with vitamin- E (group IV) on day 7th and day 14th post-treatment was found to be 50 percent and <100 percent respectively.
Table 3: Oxidative stress parameters in various groups of equines suffering from Trypanosoma evansi infection (Mean ± SE)
Groups | LPO (nmolMDA/mg Hb) | SOD (U/mgHb) | Catalase (U/mgHb) | ||||||
Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | Day 0 | Day 7th | Day 14th | |
I | 21.93±0.60Bb | 16.7±0.12Ca | 16.04±0.04Ca | 3.15±0.06Aa | 4.18±0.04Bb | 4.53±0.07Dc | 1.74±0.16Ba | 2.58±0.09Db | 2.91±0.10Db |
II | 21.98±0.45Bc | 14.8±0.09Bb | 13.99±0.04Ba | 3.05±0.19Aa | 5.7±0.18Cb | 6.23±0.10Ec | 1.83±0.14Ba | 3.28±0.05Eb | 3.9±0.06Ec |
III | 21.9±0.32Bc | 18.98±0.09Fb | 18.21±0.14Fa | 3.16±0.05Aa | 3.56±0.06Ab | 3.92±0.08Ac | 1.41±0.06Aa | 1.83±0.05Ab | 1.98±0.04Ac |
IV | 21.77±0.41Bc | 17.82±0.08Db | 16.92±0.16Da | 3.13±0.04Aa | 3.99±0.03Bb | 4.27±0.06BCc | 1.34±0.06Aa | 2.16±0.04Bb | 2.49±0.04Cc |
V | 21.7±0.47Bb | 18.39±0.18Ea | 17.66±0.11Ea | 3.12±0.06Aa | 3.75±0.06Ab | 4.11±0.09ABc | 1.57±0.09ABa | 2.01±0.06Bb | 2.27±0.07Bc |
VI | 22.06±0.46Bb | 16.74±0.13Ca | 16.05±0.03Ca | 3.12±0.06Aa | 4.09±0.04Bb | 4.48±0.09CDc | 1.59±0.11ABa | 2.34±0.08Cb | 2.63±0.04Cc |
VII | 13.07±0.07A | 12.81±0.16A | 12.93±0.13A | 7.12±0.04B | 7.14±0.06D | 7.16±0.03F | 5.14±0.03C | 5.22±0.02F | 5.2±0.01F |
Mean with different superscript (A, B, C, D) in columns are differing significantly in between the groups, otherwise non-significant; Mean with different superscript (a, b, c) in rows are differing significantly in between the intervals, otherwise non-significant
Therefore, on the basis of percent recovery assessment diaminazine aceturate alone or in combination with Vitamin E was found to best, followed by isometamedium along with vitamin E and quinopyramine sulphate alone or in combination with the Vitamin E, found to be least effective in treating clinical trypanosomiasis in equines. During entire study no any adverse reactions were observed after administration of antitrypanosomal drugs, this might be due to fact we had instituted proper supportive therapies before administration of antitrypanosomal drugs. In present investigation single dose administration of isometamedium and quinopyramine were not effective to control the T. evansi infection, it can be correlated with the possible causes of present findings where one animal of group V & VI and two animals of group III & IV were found again blood smear positive after the day 7th of treatment with their respective drugs. This could also be due to the facts that indiscriminate use of isometamidium chloride hydrochloride and quinopyramine sulphate could leads to development of resistance among trypanosomes (Howes et al., 2011).
Conclusion
In conclusion it can be said from present study that diaminazine aceturate along with vitamin E and other supportive therapies in the recommended doses could be used to treat clinical cases of Trypanosoma evansi infection in equines with great success than other antitrypanosomal drugs currently available.
Acknowledgement
Authors are thankful to the Dr S. K. Garg, Dean, COVSc &AH and Dr P K Shukla, Dean Post graduate studies DUVASU, Mathura, for providing necessary facilities and support during the investigation.
References